Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction
Myocardial Infarction, Inflammation, Endothelial Dysfunction
About this trial
This is an interventional prevention trial for Myocardial Infarction focused on measuring myocardial infarction, inflammation, endothelial dysfunction
Eligibility Criteria
Inclusion Criteria:
- Less than 24 hours after the onset of MI symptoms
- ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
- Myocardial necrosis, as evidenced by increased CK-MB and troponin levels
Exclusion Criteria:
- Use of statins for at least 6 months prior the myocardial infarction
Sites / Locations
- Hospital de Base do Distrito Federal
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
Experimental
Experimental
Experimental
No lipid-lowering
Simvastatin 20 mg
Simvastatin 40 mg
Simvastatin 80 mg
No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment